Analysts Set Medexus Pharmaceuticals Inc. (TSE:MDP) PT at C$5.49

Medexus Pharmaceuticals Inc. (TSE:MDP) has earned an average recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, one has given a buy recommendation and four have given a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is C$5.49.

MDP has been the topic of a number of recent research reports. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial raised shares of Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a research report on Wednesday, January 8th. Finally, Ventum Financial increased their price objective on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a report on Thursday, January 30th.

Medexus Pharmaceuticals Stock Performance

Medexus Pharmaceuticals stock opened at C$2.04 on Friday. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56. The firm’s 50-day moving average is C$2.80 and its 200-day moving average is C$2.90. The company has a market cap of C$45.67 million, a P/E ratio of 9.76 and a beta of 1.96.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.